Pyxis Oncology Inc (PYXS)
3.28
+0.07
(+2.18%)
USD |
NASDAQ |
Jun 28, 16:00
3.28
0.00 (0.00%)
After-Hours: 20:00
Pyxis Oncology Cash from Investing (Quarterly): -18.50M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -18.50M |
| December 31, 2023 | 10.23M |
| September 30, 2023 | 6.571M |
| June 30, 2023 | -22.26M |
| March 31, 2023 | -99.39M |
| December 31, 2022 | -1.858M |
| September 30, 2022 | -4.266M |
| Date | Value |
|---|---|
| June 30, 2022 | -0.129M |
| March 31, 2022 | -0.146M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | -0.371M |
| March 31, 2021 | -0.219M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-99.39M
Minimum
Mar 2023
10.23M
Maximum
Dec 2023
-10.03M
Average
-0.219M
Median
Mar 2021
Cash from Investing (Quarterly) Benchmarks
| Syndax Pharmaceuticals Inc | -99.40M |
| NovaBay Pharmaceuticals Inc | 1.068M |
| Palatin Technologies Inc | 0.00 |
| iBio Inc | 1.00M |
| Theriva Biologics Inc | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.71M |
| Cash from Financing (Quarterly) | 57.51M |
| Free Cash Flow | -67.14M |
| Free Cash Flow Per Share (Quarterly) | -0.4084 |
| Free Cash Flow Yield | -46.65% |